The pharmacokinetics of xamoterol in liver disease.
The pharmacokinetics of xamoterol, a beta 1-adrenoceptor partial agonist, have been studied in patients with liver disease and a group of age- and sex-matched normal controls. No significant differences were observed after the oral administration of xamoterol 200 mg. The low bioavailability of xamoterol was confirmed (6.1% in patients, 6.9% in controls). After i.v. xamoterol 0.2 mg kg-1, no significant differences between the groups were observed. A small increase in the terminal plasma elimination half-life (t1/2) was observed in patients when compared with controls (15.3 +/- 6.4 vs 8.4 +/- 2.8 h, mean +/- s.d., P = 0.08). Renal clearance accounted for about 50% of total clearance in patients and about 30% in controls. It is suggested that in patients with heart failure, hepatic dysfunction would probably not influence xamoterol disposition.
Nicholls
D P
DP
Royal Victoria Hospital, Belfast, Northern Ireland.
Taggart
A J
AJ
McCann
J P
JP
Bastain
W
W
Shanks
R G
RG
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008107:Liver Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000493:pharmacokinetics* / Q000494:pharmacology; D011863:Radioimmunoassay; D017307:Xamoterol
D011412:Propanolamines; D017307:Xamoterol